Voyager Therapeutics Inc (NASDAQ: VYGR) has reported E.P.S. of $-0.18 for its second fiscal quarter (ending June 30) versus $-0.51 for the same period a year ago. This result exceeded the consensus estimate of $-0.40 by $0.22. For the latest four quarters through June 30, E.P.S. were $0.32 versus $2.27 for the same period a year ago — a decline of -86%.
Recent Price Action
Voyager Therapeutics Inc (NASDAQ: VYGR) stock closed at $8.19 on 8/6/24 after a large increase of 2.8%. However, trading volume in this advance was below average at 75% of normal. Relative to the market the stock has been strong over the last nine months but has declined -10.2% during the last week.
Current PriceTarget Research Rating
VYGR’s future returns on capital are forecasted to fall short of the cost of capital. Accordingly, the company is expected to be a modest Value Eraser.
Voyager Therapeutics has a current Value Trend Rating of C (Low Neutral). The Value Trend Rating reflects contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Voyager Therapeutics has a poor Appreciation Score of 26 but a slightly positive Power Rating of 68, resulting in the Low Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment